Purpura fulminans in an adult patient with Haemophilus influenzae sepsis: case report and review of the literature.
Purpura fulminans is a rare complication of a coagulopathy or an infection. Haemophilus influenzae infection, which has decreased since the haemophilus influenzae type B vaccine was initiated, is an unusual initiating cause of purpura fulminans. This case is the first reported in the literature of an adult who developed purpura fulminans after Haemophilus influenzae sepsis. Her elevated beta2 glycoprotein 1 ratio may have contributed to the severity of her disease. Although rare, Haemophilus influenzae may precipitate purpura fulminans. Current therapy is directed at control of precipitating factors, removal of nonviable tissue, treatment of secondary infections, and physiologic support. There also is evidence that patients respond well to hyperbaric oxygen therapy, with decreasing limb and tissue loss.
Gast
Thomas
T
Department of Trauma, Sumner L. Koch Burn Center, John H. Stroger, Jr., Hospital of Cook County, Chicago, Illinois 60612, USA.
Kowal-Vern
Areta
A
An
Gary
G
Hanumadass
Marella L
ML
D000328:Adult; D000671:Amputation, Surgical; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002443:Ceftriaxone / Q000627:therapeutic use; D005260:Female; D006023:Glycoproteins / Q000097:blood; D006192:Haemophilus Infections / Q000175:diagnosis* / Q000188:drug therapy; D006193:Haemophilus influenzae / Q000302:isolation & purification*; D006801:Humans; D011695:IgA Vasculitis / Q000175:diagnosis* / Q000628:therapy; D018805:Sepsis / Q000188:drug therapy / Q000382:microbiology*; D053482:beta 2-Glycoprotein I
D000900:Anti-Bacterial Agents; D006023:Glycoproteins; D053482:beta 2-Glycoprotein I; D002443:Ceftriaxone